Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 1536489A (Primary) ; Influenza virus vaccine
Indications Influenza virus infections
Focus Adverse reactions; Pharmacodynamics
Sponsors GlaxoSmithKline; GSK

Most Recent Events

19 Feb 2018 Results of pooled post hoc analysis of NCT00764790, NCT00980005 and NCT00383123 trials assessing the relation of fever and antipyretic use to each other and to vaccine immunogenicity published in the Pediatric Infectious Disease Journal
10 Feb 2012 Results published in the Pediatric Infectious Disease Journal.
10 Feb 2012 Primary endpoint 'Seroconversion-rate' has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com